259 related articles for article (PubMed ID: 11376349)
1. [In vitro activity of linezolid against clinical isolates of methicillin-resistant Staphylococcus aureus].
Pérez L; Alarcón T; Jiménez S; de Las Cuevas MC; López-Brea S
Rev Esp Quimioter; 2001 Mar; 14(1):47-50. PubMed ID: 11376349
[TBL] [Abstract][Full Text] [Related]
2. [Sensitivity of methicillin resistant staphylococci to linezolid and some other antimicrobial agents].
Ertek M; Yazgi H; Aktaş E; Ayyildiz A; Parlak M
Mikrobiyol Bul; 2003 Oct; 37(4):235-40. PubMed ID: 14748259
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility of methicillin-resistant Staphylococcus aureus to vancomycin, teicoplanin, linezolid, pristinamycin and other antibiotics.
Samra Z; Ofer O; Shmuely H
Isr Med Assoc J; 2005 Mar; 7(3):148-50. PubMed ID: 15792257
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods.
Jacqueline C; Caillon J; Le Mabecque V; Miegeville AF; Donnio PY; Bugnon D; Potel G
J Antimicrob Chemother; 2003 Apr; 51(4):857-64. PubMed ID: 12654769
[TBL] [Abstract][Full Text] [Related]
5. Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections.
Stein GE; Schooley S; Peloquin CA; Missavage A; Havlichek DH
J Antimicrob Chemother; 2007 Oct; 60(4):819-23. PubMed ID: 17673476
[TBL] [Abstract][Full Text] [Related]
6. Linezolid alone and in combination with rifampicin prevents experimental vascular graft infection due to methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis.
Sacar M; Sacar S; Kaleli I; Onem G; Turgut H; Goksin I; Ozcan V; Kaan Inan B; Duver H; Baltalarli A
J Surg Res; 2007 May; 139(2):170-5. PubMed ID: 17292421
[TBL] [Abstract][Full Text] [Related]
7. Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey.
Baysallar M; Kilic A; Aydogan H; Cilli F; Doganci L
Int J Antimicrob Agents; 2004 May; 23(5):510-2. PubMed ID: 15120733
[TBL] [Abstract][Full Text] [Related]
8. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan.
Huang YT; Liao CH; Teng LJ; Hsueh PR
Clin Microbiol Infect; 2008 Feb; 14(2):124-9. PubMed ID: 18076671
[TBL] [Abstract][Full Text] [Related]
9. Susceptibility to daptomycin, quinupristin-dalfopristin and linezolid and some other antibiotics in clinical isolates of methicillin resistant and methicillin sensitive S.aureus from the Oslo area.
Jørgen B; Merckoll P; Melby KK
Scand J Infect Dis; 2007; 39(11-12):1059-62. PubMed ID: 17852934
[TBL] [Abstract][Full Text] [Related]
10. [Activity of vancomycin, teicoplanin and linezolid in methicillin resistant coagulase-negative Staphylococci isolates from paediatric blood cultures].
Fajardo Olivares M; Hidalgo Orozco R; Rodríguez Garrido S; Gaona Álvarez C; Sánchez Silos RM; Hernández Rastrollo R; Martínez Tallo E; Cordero Carrasco JL
Rev Esp Quimioter; 2012 Mar; 25(1):25-30. PubMed ID: 22488538
[TBL] [Abstract][Full Text] [Related]
11. [In vitro susceptibility to linezolid in methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus strains].
Efe S; Sinirtaş M; Ozakin C
Mikrobiyol Bul; 2009 Oct; 43(4):639-43. PubMed ID: 20084917
[TBL] [Abstract][Full Text] [Related]
12. The post-antibiotic effects of linezolid against Gram-positive pathogens.
Hosgor-Limoncu M; Ermertcan S; Tasli H; Aydemir S
Saudi Med J; 2007 Apr; 28(4):551-4. PubMed ID: 17457476
[TBL] [Abstract][Full Text] [Related]
13. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.
Steinkraus G; White R; Friedrich L
J Antimicrob Chemother; 2007 Oct; 60(4):788-94. PubMed ID: 17623693
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro activity of linezolid and five other antimicrobials against nosocomial isolates of methicillin-resistant Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis and vancomycin-resistant Enterococcus faecium.
Metallidis S; Chatzidimitriou M; Nikolaidis P; Tsona A; Bisiklis A; Kollaras P; Tsiakiri E; Koumentaki E; Alexiou-Daniel S
J Chemother; 2003 Oct; 15(5):442-8. PubMed ID: 14603881
[TBL] [Abstract][Full Text] [Related]
15. In vitro susceptibility of staphylococci to linezolid and other antimicrobial agents.
Poiată A; Tuchiluş C; Bădicuţ I; Grigore L; Buiuc D
Roum Arch Microbiol Immunol; 2002; 61(4):293-9. PubMed ID: 15055263
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil.
Kuti JL; Kiffer CR; Mendes CM; Nicolau DP
Clin Microbiol Infect; 2008 Feb; 14(2):116-23. PubMed ID: 18076672
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of ceftobiprole, linezolid, tigecycline, and 23 other antimicrobial agents against Staphylococcus aureus isolates in China.
Wang H; Liu Y; Sun H; Xu Y; Xie X; Chen M
Diagn Microbiol Infect Dis; 2008 Oct; 62(2):226-9. PubMed ID: 18653301
[TBL] [Abstract][Full Text] [Related]
18. Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype.
Pillai SK; Sakoulas G; Wennersten C; Eliopoulos GM; Moellering RC; Ferraro MJ; Gold HS
J Infect Dis; 2002 Dec; 186(11):1603-7. PubMed ID: 12447736
[TBL] [Abstract][Full Text] [Related]
19. Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program.
Anderegg TR; Sader HS; Fritsche TR; Ross JE; Jones RN
Int J Antimicrob Agents; 2005 Jul; 26(1):13-21. PubMed ID: 15967640
[TBL] [Abstract][Full Text] [Related]
20. Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program.
Ross JE; Anderegg TR; Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 May; 52(1):53-8. PubMed ID: 15878443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
